Targeting pathways downstream of KRAS in lung adenocarcinoma

Pharmacogenomics

Volumn 15, Issue 11, 2014, Pages 1507-1518

  Zhu, Zehua ^a,b   Golay, Hadrien G ^a,c   Barbie, David A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c EPFL   (Switzerland)

Author keywords

autophagy; AZD6244; CYT387; cytokines; KRAS; lung cancer; OSI 906; PI3K; RAF; RAL GEF

Indexed keywords

AMG 379; ANTINEOPLASTIC AGENT; BINIMETINIB; BUPARLISIB; COBIMETINIB; DACTOLISIB; DOCETAXEL; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; K RAS PROTEIN; LINSITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MOMELOTINIB; MSC 1936369B; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN BCL XL; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SAR 245409; SELUMETINIB; SOMATOMEDIN C RECEPTOR; TRAMETINIB; UNCLASSIFIED DRUG; CYTOKINE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; LUNG ADENOCARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ADENOCARCINOMA; ANIMAL; CELL TRANSFORMATION; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM;

ADENOCARCINOMA; ANIMALS; AUTOPHAGY; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84907936482     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.108     Document Type: Review

References (85)

1. Porta M, Crous-Bou M, Wark PA, et al. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat. Res. 682(2-3), 83-93 (2009).
2. Holstein SA, Hohl RJ. Is there a future for prenyltransferase inhibitors in cancer therapy?. Curr. Opin. Pharmacol. 12(6), 704-709 (2012).
3. Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497(7451), 638-642 (2013).
4. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477), 548-551 (2013).
5. Lim SM, Westover KD, Ficarro SB, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed. Engl. 53(1), 199-204 (2014).
6. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3(14), 1787-1808 (2011).
7. Weinberg RA. Hunting the elusive oncogene: a stroke of good luck. Nat. Cell Biol. 13(8), 876 (2011).
8. Bonner TI, Kerby SB, Sutrave P, Gunnell MA, Mark G, Rapp UR. Structure and biological activity of human homologs of the raf/mil oncogene. Mol. Cell. Biol. 5(6), 1400-1407 (1985).
9. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-Activated protein kinase kinase. Science 260(5114), 1658-1661 (1993).
10. White MA, Nicolette C, Minden A, et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell 80(4), 533-541 (1995).
11. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369(6479), 411-414 (1994).
12. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane. Science 264(5164), 1463-1467 (1994
13. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89(3), 457-467 (1997).
14. White MA, Vale T, Camonis JH, Schaefer E, Wigler MH. A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation. J. Biol. Chem. 271(28), 16439-16442 (1996).
15. Urano T, Emkey R, Feig LA. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J. 15(4), 810-816 (1996).
16. Okazaki M, Kishida S, Murai H, Hinoi T, Kikuchi A. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells. Cancer Res. 56(10), 2387-2392 (1996).
17. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 400(6743), 464-468 (1999).
18. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16(16), 2045-2057 (2002).
19. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species-And cell type-specific requirements for cellular transformation. Cancer Cell 6(2), 171-183 (2004).
20. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15(24), 3243-3248 (2001).
21. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-Ras oncogene is highly dependent on cellular context. Cancer Cell 4(2), 111-120 (2003).
22. Karreth FA, Frese KK, Denicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 1(2), 128-136 (2011).
23. Blasco RB, Francoz S, Santamaria D, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-Driven non-small cell lung carcinoma. Cancer Cell 19(5), 652-663 (2011).
24. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-Driven tumorigenesis in mice. Cell 129(5), 957-968 (2007).
25. Castellano E, Sheridan C, Thin MZ, et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell 24(5), 617-630 (2013).
26. Peschard P, Mccarthy A, Leblanc-Dominguez V, et al. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Curr. Biol. 22(21), 2063-2068 (2012).
27. Demetri GD, Ernst TJ, Pratt ES 2nd, Zenzie BW, Rheinwald JG, Griffin JD. Expression of Ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J. Clin. Invest. 86(4), 1261-1269 (1990).
28. Castelli C, Sensi M, Lupetti R, et al. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res. 54(17), 4785-4790 (1994).
29. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6(5), 447-458 (2004).
30. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21(14), 1714-1719 (2007).
31. Tan X, Carretero J, Chen Z, et al. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-Driven murine lung cancer. PLoS ONE 8(11), e80885 (2013).
32. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19(4), 456-469 (2011).
33. Ancrile BB, O'Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol. Interv. 8(1), 22-27 (2008).
34. Gong L, Cumpian AC, Caetano MS, et al. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol. Cancer 12(1), 154 (2013).
35. Kumar MS, Hancock DC, Molina-Arcas M, et al. The GATA2 transcriptional network is requisite for Ras oncogene-Driven non-small cell lung cancer. Cell 149(3), 642-655 (2012).
36. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462(7269), 104-107 (2009).
37. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13(4), 343-354 (2008).
38. Basseres DS, Ebbs A, Levantini E, Baldwin AS. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70(9), 3537-3546 (2010).
39. Xia Y, Yeddula N, Leblanc M, et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat. Cell Biol. 14(3), 257-265 (2012).
40. Chien Y, Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127(1), 157-170 (2006).
41. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129(6), 1065-1079 (2007).
42. Barbie DA, Tamayo P, Boehm JS, et al Systematic RNA interference reveals that oncogenic KRAS-Driven cancers require TBK1. Nature 462(7269), 108-112 (2009).
43. Ou YH, Torres M, Ram R, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol. Cell 41(4), 458-470 (2011
44. Rajurkar M, De Jesus-Monge WE, Driscoll DR, et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc. Natl Acad. Sci. USA 109(17), E1038-E1047 (2012).
45. Newman AC, Scholefield CL, Kemp AJ, et al. TBK1 kinase addiction in lung cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-kappaB signalling. PLoS ONE 7(11), e50672 (2012).
46. Guo J, Kim D, Gao J, et al. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene 32(2), 151-159 (2013).
47. Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-Driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 4(4), 452-465 (2014).
48. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev. 25(19), 1999-2010 (2011).
49. Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25(7), 717-729 (2011).
50. Guo JY, Chen HY, Mathew R, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25(5), 460-470 (2011).
51. Lock R, Roy S, Kenific CM, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol. Biol. Cell 22(2), 165-178 (2011).
52. Kim MJ, Woo SJ, Yoon CH, et al. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J. Biol. Chem. 286(15), 12924-12932 (2011).
53. Guo JY, Karsli-Uzunbas G, Mathew R, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27(13), 1447-1461 (2013).
54. Rao S, Tortola L, Perlot T, et al. A dual role for autophagy in a murine model of lung cancer. Nat. Commun. 5, 3056 (2014).
55. Lock R, Kenific CM, Leidal AM, Salas E, Debnath J. Autophagy-Dependent production of secreted factors facilitates oncogenic RAS-Driven invasion. Cancer Discov. 4(4), 466-479 (2014).
56. Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24(2), 213-228 (2013).
57. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 39(2), 91-100 (2014).
58. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic KRAS maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3), 656-670 (2012).
59. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496(7443), 101-105 (2013).
60. Denicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354), 106-109 (2011).
61. Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res. 73(13), 4158-4168 (2013).
62. De Raedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-Driven tumors. Cancer Cell 20(3), 400-413 (2011).
63. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5), 835-848 (2009).
64. Puyol M, Martin A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18(1), 63-73 (2010).
65. Hata AN, Yeo A, Faber AC, et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers. Cancer Res. 74(11), 3146-3156 (2014).
66. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14(12), 1351-1356 (2008).
67. Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-Dependent efficacy of single and combined PI3K-And MAPK-pathway inhibition in cancer. Proc. Natl Acad. Sci. USA 106(43), 18351-18356 (2009).
68. Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-Driven cancers. Nature 501(7466), 232-236 (2013).
69. Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483(7391), 613-617 (2012).
70. Corcoran RB, Cheng KA, Hata AN, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23(1), 121-128 (2013).
71. Aparicio CB, Renner O, Gomez-Casero E, et al. Co-Targeting PIM and PI3K/mTOR pathways with a single molecule: novel orally available combined PIM/Pi3K and PIM/PI3K/mTOR kinase inhibitors. Mol. Cancer Ther. 12(11 Suppl.), A275 (2013).
72. Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 3(5), 548-563 (2013
73. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, Phase 2 study. Lancet Oncol. 14(1), 38-47 (2013).
74. Lito P, Saborowski A, Yue J, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25(5), 697-710 (2014).
75. Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-Associated IL-6/IL-8 cytokine network. Proc. Natl Acad. Sci. USA 106(40), 17031-17036 (2009).
76. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-Dependent inflammatory network. Cell 133(6), 1019-1031 (2008).
77. Bodemann BO, Orvedahl A, Cheng T, et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome assembly. Cell 144(2), 253-267 (2011).
78. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 27(6), 1322-1327 (2013).
79. Xue W, Meylan E, Oliver TG, et al. Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 1(3), 236-247 (2011).
80. Strickson S, Campbell DG, Emmerich CH, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem. J. 451(3), 427-437 (2013).
81. Shackelford DB, Abt E, Gerken L, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23(2), 143-158 (2013).
82. Li L, Han R, Xiao H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin. Cancer Res. 20(10), 2714-2726 (2014).
83. Shapiro GI, Rosen LS, Tolcher AW, et al. First-in-human Phase 1 study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J. Clin. Oncol. 31(Suppl.), Abstract 2500 (2013).
84. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155), 807-810 (2007).
85. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst. 104(3), 228-239 (2012